Trial Profile

A phase II/III trial assessing satoreotide in patients with neuroendocrine tumors

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 20 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium 68 satoreotide (Primary) ; Lutetium 177 satoreotide tetraxetan (Primary)
Indications Neuroendocrine tumours
Focus Therapeutic Use
Sponsors Ipsen

Most Recent Events

20 May 2019 New trial record
14 May 2019 According to a Ipsen media release, this trial is expected to commence in the first quarter of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com